Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

24. Februar 2016 06:00 ET | Quelle: Mesoblast Limited

First Allogeneic Cell Therapy Product Launched in Japan by Mesoblast Licensee

NEW YORK and MELBOURNE, Australia, Feb. 24, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) announced that its licensee in Japan, JCR Pharmaceuticals Co. Ltd., today launched...
22. Februar 2016 05:00 ET | Quelle: Mesoblast Limited

Mesoblast’s Cell Therapy Increases Survival in Children With Acute Graft Versus Host Disease

NEW YORK and MELBOURNE, Australia, Feb. 22, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB;) today announced that results have been presented showing that use of its proprietary...
16. Februar 2016 16:40 ET | Quelle: Mesoblast Limited

Mesoblast Reports on First Half and Second Quarter Financial Results

MELBOURNE, Australia and NEW YORK, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today reported financial results and operational highlights for the 1H/2Q ended 31...
16. Februar 2016 06:00 ET | Quelle: Mesoblast Limited

Mesoblast Cell Therapy Shows Clinical Benefit in First Cohort of Patients With Biologic Refractory Rheumatoid Arthritis

NEW YORK and MELBOURNE, Australia, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced results from the first cohort of its ongoing Phase 2 trial in...
11. Februar 2016 11:00 ET | Quelle: Mesoblast Limited

Mesoblast to Host Second Quarter and First Half Financial Results Conference Call and Webcast

MELBOURNE, Australia and NEW YORK, Feb. 11, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the second quarter/half year...
11. Januar 2016 08:00 ET | Quelle: Mesoblast Limited

Phase 3 Heart Failure Trial Size to be Substantially Reduced Following FDA Discussions

NEW YORK and MELBOURNE, Australia, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that the size of the ongoing Phase 3 trial in chronic heart failure...
07. Januar 2016 17:56 ET | Quelle: Mesoblast Limited

Mesoblast to Present at the 34th Annual J. P. Morgan Healthcare Conference

MELBOURNE, Australia and NEW YORK, Jan. 07, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that it will present at the 34th Annual J. P. Morgan Healthcare...
16. Dezember 2015 16:57 ET | Quelle: Mesoblast Limited

Mesoblast Provides Strategic Update and Reports on First Quarter Financial Results

Materially Strengthened Cash Reserves First Royalties From TEMCELL Product Sales Expected In Q1 2016 Resources Prioritized On Tier 1 Product Candidates Cash Managed To Extend Runway And Achieve...
15. Dezember 2015 19:50 ET | Quelle: Mesoblast Limited

Mesoblast to Host First Quarter Financial Results Conference Call and Webcast on 16 December 2015

MELBOURNE, Australia and NEW YORK, Dec. 15, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced it will report financial results for the quarter ended 30 September...
27. November 2015 06:00 ET | Quelle: Mesoblast Limited

Mesoblast’s Japan Licensee Receives Pricing for TEMCELL® HS Inj. for Treatment of Acute Graft Versus Host Disease

MELBOURNE, Australia and NEW YORK, Nov. 27, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that its licensee in Japan, JCR Pharmaceuticals Co. Ltd., has received...

Vorherige Seite